Finasteride, A Steroid 5α-Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Most hair loss treatments are ineffective; only finasteride, dutasteride, and minoxidil show effectiveness.

Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.

The conversation discusses the side effects of finasteride, including low libido and erectile dysfunction, and the possibility of these effects being permanent, known as post-finasteride syndrome (PFS). Some users report personal experiences with PFS and debate whether the condition is real, with varying opinions on the reversibility of side effects and the role of individual biology.

Finasteride significantly increased testosterone levels for the user, with no major side effects except watery semen, which was resolved with zinc supplements. The user's hairline stopped receding and slightly improved.